Premier Alternatives

Enterome

Paris, France · Founded 2008 · Privately Held (backing)

Developer of pharmaceuticals and diagnostic tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor types. Enterome is based in Paris, France and was founded in 2008. Its last reported valuation was $217 million in Jul 2022. It has raised $292 million.

Last reported valuation
$217.0M
Oct 2026
Priced at
—
Total raised
$292.3M
Last round
—

Enterome key facts

as of Oct 2026
  • Developer of pharmaceuticals and diagnostic tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor types.
  • Enterome is valued at approximately $217.0M as of Oct 2026 (last reported valuation).
  • It has raised $292.3M; the latest was Later Stage VC ($19.0M) in Jun 2025.
  • Notable investors include Omnes Capital, Bristol-Myers Squibb, Primo Capital (Milano), Takeda Ventures, Nestlé Health Science — 18 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$217.0M

Enterome's last reported valuation, Jul 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Enterome with a free account
  • ·The complete investor list: 18 names
  • ·Watch Enterome: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Enterome funding rounds

No rounds on record

No funding rounds for Enterome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Enterome valuation

Enterome's last reported valuation was $217 million in Jul 2022. No priced round, secondary trade or fund mark has surfaced since.

Enterome investors

18 investors are on record for Enterome, including Omnes Capital, Bristol-Myers Squibb, Primo Capital (Milano) and Takeda Ventures.

About Enterome

Developer of pharmaceuticals and diagnostic tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor types. The company's approach generates a powerful, long-lasting immune response from the patient's own effector memory T-cells, overcoming the immune tolerance to self-antigens, integrated with a research and development platfo, with therm potential to deliver multiple candidates with a rapid progression, overcoming the immune tolerance to self-antigens, enabling healthcare companies to begin treatment more quickly and resulting in a likelihood of successful treatment.

Sector
Healthcare
HQ
Paris, France
Founded
2008
Employees
78
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.